细胞学不确定的甲状腺结节患者若组织学为癌,其结局优于可疑或恶性细胞学患者
本研究比较了371例细胞学Thy 3(不确定)与269例Thy 4-5(可疑或恶性)且均行全甲状腺切除和131I治疗患者的结局。Thy 3组T1期占46.0%、N0占95.9%,均高于Thy 4-5组的38.8%和75.5%;Thy 3组需>30 mCi 131I者9.6%,低于Thy 4-5组的31.5%;随访结束时无病率Thy 3组96.8%,高于Thy 4-5组的86.2%。结论:Thy 3细胞学患者甲状腺癌结局更好,且更常见侵袭性较低的滤泡亚型乳头状癌。
要点
- Thy 3细胞学患者组织学为癌时,T1期和N0比例更高,需较大剂量131I者更少。
- Thy 3组无病生存率96.8%,高于Thy 4-5组的86.2%。
- Thy 3组达50%缓解仅需2年,Thy 4-5组需4年。
核心结论
- 细胞学Thy 3的患者甲状腺癌结局优于Thy 4或Thy 5患者,且不确定细胞学常与侵袭性较低的滤泡亚型乳头状癌相关。
研究设计与样本
- 回顾性比较371例细胞学Thy 3与269例Thy 4-5且均行全甲状腺切除和131I治疗的患者。
主要发现
- T1期占46.0% vs 38.8%(p=0.02),N0占95.9% vs 75.5%(p<0.0001)。
- 需>30 mCi 131I者占9.6% vs 31.5%(p<0.0001)。
- 随访结束无病者占96.8% vs 86.2%(p<0.001)。
- 50%患者达缓解所需时间Thy 3组2年,Thy 4-5组4年(p<0.001)。
- Thy 3组最常见组织学类型为FV-PTC(64.4%),Thy 4-5组为经典型(68.8%)。
关键数值与推荐
- Thy 3组T1期46.0%、N0 95.9%;Thy 4-5组T1期38.8%、N0 75.5%。
- Thy 3组需>30 mCi 131I者9.6%,Thy 4-5组31.5%。
- Thy 3组无病率96.8%,Thy 4-5组86.2%。
- FV-PTC患者T1期48.0%、N0 96.0%,其他变异型分别为40.0%和79.8%。
- FV-PTC无病率96.4%,其他变异型89.0%。
临床怎么用
- Thy 3细胞学患者组织学为癌时预后较好,可考虑个体化降低辅助治疗强度。
- Thy 3细胞学常对应FV-PTC,其侵袭性较低,支持对不确定结节采取更保守的管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcomes of patients with thyroid cancer proven by histology in patients in whom cytology was Thy 3 (indeterminate; Thy 3 patients in this study) based on the Italian consensus classification compared with those in whom cytology was Thy 4 (suspicious for malignancy) or Thy 5 (indicative for malignancy) (Thy 4-5 patients here) remains unclear. OBJECTIVE: To analyze the outcome of 371 Thy 3 patients versus 269 Thy 4-5 patients homogeneously treated with total thyroidectomy and 131I activity. RESULTS: T1 stage was observed in 46.0% of Thy 3 and in 38.8% of Thy 4-5 patients (p = 0.02), N0 in 95.9% of Thy 3 and in 75.5% of Thy 4-5 patients (p < 0.0001). 35/261 (9.6%) Thy 3 and 85/269 (31.5%) Thy 4-5 patients required >30 mCi of 131I (p < 0.0001). 359/371 (96.8%) Thy 3 and 232/269 (86.2%) Thy 4-5 patients were free of disease at the end of follow-up (p < 0.001). The time required to obtain 50% of patients in remission was 2 years in Thy 3 and 4 years in Thy 4-5 patients (p < 0.001). The most common histological type was the follicular variant of papillary thyroid carcinoma (FV-PTC) in Thy 3 patients (239/371, 64.4%) and the classic variant in Thy 4-5 patients (185/269; 68.8%). The FV-PTC had better prognostic features compared with the other PTC variants: T1 stage was observed in 133/277 (48.0%) FV-PTC patients and in 146/363 (40.0%) patients with the other variants (p < 0.001), N0 was present in 265/277 (96.0%) FV-PTC and in 290/363 (79.8%) patients with the other variants (p < 0.001). Overall, 267/277 FV-PTC patients (96.4%) and 324/363 patients (89.0%) with the other variants were free of disease (p < 0.0008) at the end of follow-up, and the time required to obtain 50% of patients in remission was 2 years in FV-PTC and 4.0 years in the other variants (p < 0.001). CONCLUSION: Patients with Thy 3 cytology have better outcomes of thyroid cancer compared with patients with Thy 4 or Thy 5 cytology, and indeterminate cytology is commonly associated with the less aggressive FV-PTC.
引用
- Rago T, Scutari M, Loiacono V, et al. Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. Thyroid. 2018. PMID: 30132418. doi:10.1089/thy.2017.0522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。